按学科分区

ONCOLOGY Q1

ONCOLOGY Q2

《Cancer Drug Resistance》(E-ISSN: 2578-532X) 是一本国际同行评审、金色开放获取期刊。专注于肿瘤耐药机制与逆转策略的专业型开放获取期刊，致力于发表从分子基础到临床转化的创新性研究成果。期刊采用国际化编委会协同工作的模式，由活跃在全球一线的科学家把握学术方向，确保所刊发内容的前沿性与严谨性，呈现各类高质量研究。在保持全球视野的同时，期刊高度关注中国学者在该领域的学术贡献，致力于打造一个专业、包容、高效的学术交流平台。 Aims & Scope链接：https://www.oaepublish.com/cdr/aims_and_scope Author Instructions链接：https://www.oaepublish.com/cdr/author_instructions Editorial Board链接：https://www.oaepublish.com/cdr/editor 文章处理费链接：https://www.oaepublish.com/cdr/article_processing_charges Cancer Drug Resistance is a continuously published journal committed to the rapid publication of high quality, peer-reviewed, original researches. The journal publishes research articles, reviews, commentaries and letters on pharmacological aspects of drug resistance and its reversal, including drug design, drug delivery, drug distribution and cellular drug resistance. Molecular mechanisms of drug resistance also cover the cellular pharmacology of drug resistance such as influx and efflux pumps (including the ABC pumps), receptors and their ligands, cellular signaling pathways, drug activation and degradation (including Phase I and II metabolism), drug sequestration, target modification and DNA repair. Drug classes to be covered include DNA targeted drugs and antihormones as well as antibodies and protein kinase inhibitors. Both clinical and experimental aspects of drug resistance in cancer are included.